Mobocertinib

Active Ingredient: Mobocertinib
Form: Capsule
Brand Name: Exkivity
Generic Name: Mobonib
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Exkivity is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Dosage and Administration:
The recommended dose is 160 mg orally once daily, with or without food. Capsules must be swallowed whole and should not be crushed or opened. If a dose is missed, follow your physician’s instructions.

Common Side Effects:
Diarrhea, rash, nausea, vomiting, and paronychia (nail fold inflammation). Some patients may experience interstitial lung disease.

Storage:
Store below 25°C in a cool, dry place away from light. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Exkivity and Mobocertinib?
A: Exkivity is the brand name registered by the original manufacturer. Mobocertinib is its active ingredient.

Q: Is the Exkivity sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic efficacy as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of the Exkivity generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, a leading pharmaceutical company in Bangladesh with in-house R&D, manufacturing, and quality control labs. They are certified to meet international pharmaceutical manufacturing standards. You can purchase with confidence.

Disclaimer:
This information is for reference only. Please consult your physician and refer to the official medication guide and the latest clinical research when making treatment decisions.

Drug Instructions (Package Insert):
Download Link